Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00960076 · ClinicalTrials.gov registry record · Phase 3
An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 Diabetes
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 282
- Enrollment target
NCT00960076 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 282 participants.
The verdict
NCT00960076, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 282 participants
- Enrollment target
Study Summary
The purpose of this study is to compare reduction in A1C for subjects taking Saxagliptin and Metformin XR vs. uptitrated Metformin XR.
Interventions
- DRUG Saxagliptin
- DRUG Metformin XR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 282 participants |
| Start Date | 2009-08 |
| Est. Completion | 2010-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00960076
The ClinicalTrials.gov registry entry for NCT00960076 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 282 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Saxagliptin is the first listed.
NCT00960076 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00960076 about?
NCT00960076 is a clinical study titled "An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 Diabetes". The purpose of this study is to compare reduction in A1C for subjects taking Saxagliptin and Metformin XR vs. uptitrated Metformin XR.
What is the current status of trial NCT00960076?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 282 participants. The study started on 2009-08. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00960076?
The interventions under investigation include: Saxagliptin (DRUG), Metformin XR (DRUG).
Who is sponsoring clinical trial NCT00960076?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.